RCT: Tranexamic acid for the prevention of blood loss after cesarean delivery – even though TA resulted in a significantly lower incidence of estimated blood loss, the clinical relevance of the findings was small
30 Apr, 2021 | 08:38h | UTC
Commentaries on Twitter
Another typically "positive" trial for TXA.
"the mean between-group difference was approximately 100 ml …. the clinical relevance of this narrow difference is questionable"
– No difference in RBC transfusions.
– 0.4% vs 0.1% VTE at 3 mos.— Ryan Radecki, MD MS (@emlitofnote) April 28, 2021
NEJM-Prevention of Blood Loss after Cesarean Delivery | tranexamic acid ➡️ significantly lower incidence of EBL greater than 1000 ml or RBC transfusion by day 2 than placebo, but did not result in a ⬇️ incidence of hemorrhage-related secondary outcomes https://t.co/ydF5HgHM0N
— Skeptical Scalpel (@Skepticscalpel) April 28, 2021